Table 1.
Patients’ characteristics stratified by the TRAF6 haplotype. Median/IQR or Frequency/Percentage are shown.
| rs331457 rs5030419 | All patients (N = 432) | Haplotype 1 WT (G) WT (C) (N = 208) | Haplotype 2 MUT (G>A) WT (C) (N = 102) | Haplotype 3WT (G)MUT (C>G)(N = 103) | Mixed HaplotypeMUT (G>A)MUT (C>G)(N = 19) | P value* |
|---|---|---|---|---|---|---|
| Male sex | 308 (71%) | 149 (72%) | 68 (67%) | 78 (76%) | 13 (68%) | 0.53 |
| Alcoholic cirrhosis | 325 (75%) | 154 (74%) | 79 (77%) | 78 (76%) | 14 (74%) | 0.93 |
| NOD2 risk variants # | 84 (19%) | 43 (21%) | 23 (23%) | 17 (17%) | 1 (5%) | 0.29 |
| Patient characteristics at inclusion | ||||||
| Age | 59 (52–68) | 60 (53–68) | 58 (47–68) | 59 (52–70) | 56 (52–66) | 0.43 |
| Hepatocellular carcinoma | 65 (15%) | 33 (16%) | 10 (10%) | 18 (17%) | 4 (21%) | 0.30 |
| Child-Pugh stage C | 287 (66%) | 140 (67%) | 66 (65%) | 70 (68%) | 11 (58%) | 0.80 |
| MELD | 17 (12–22) | 17 (12–22) | 18 (12–22) | 17 (12–23) | 14 (12–17) | 0.30 |
| Ascitic fluid protein (g/l) | 13 (8–20) | 13 (9–19) | 10 (8–18) | 11 (8–21) | 21 (9–32) | 0.029 |
| SAAG (g/l) | 17 (13–20) | 17 (13–20) | 17 (13–20) | 17 (12–21) | 15 (12–15) | 0.56 |
| Bilirubin (µmol/l) | 44 (22–97) | 42 (21–98) | 46 (26–92) | 48 (20–114) | 40 (24–64) | 0.95 |
| International normalized ratio | 1.4 (1.2–1.7) | 1.4 (1.2–1.7) | 1.4 (1.3–1.7) | 1.4 (1.2–1.8) | 1.4 (1.1–1.6) | 0.76 |
| Creatinine (µmol/l) | 96 (67–148) | 90 (67–147) | 108 (63–156) | 106 (69–148) | 81 (60–114) | 0.41 |
| C-reactive protein (mg/l) | 32 (17–60) | 32 (16–59) | 37 (20–62) | 33 (19–57) | 22 (12–56) | 0.68 |
| WBC (×10 9 cells/l) | 7.2 (5.0–10.8) | 7.0 (5.2–10.0) | 6.9 (4.6–12.0) | 8.0 (5.5–11.1) | 5.7 (3.9–10.2) | 0.46 |
| Platelets (×10 9 cells/l) | 129 (82–185) | 137 (87–200) | 131 (78–185) | 114 (79–181) | 90 (69–144) | 0.16 |
| Albumin (g/l) | 24 (20–28) | 24 (20–29) | 23 (20–28) | 25 (20–28) | 24 (20–31) | 0.94 |
| Sodium (mmol/l) | 135 (132–139) | 135 (131–138) | 135 (132–138) | 135 (133–139) | 136 (132–141) | 0.53 |
| Use of beta blockers | 223 (52%) | 100 (48%) | 60 (59%) | 53 (51%) | 10 (53%) | 0.36 |
| Patient characteristics during follow-up | ||||||
| Primary antibiotic prophylaxis at any time ¶ | 71 (17%) | 34 (17%) | 18 (19%) | 17 (17%) | 2 (10%) | 0.89 |
*P values from from Kruskal Wallis test or Fisher’s exact test as appropriate.
#Nucleotide-binding oligomerization domain-containing protein 2 risk variants R702W, G908R and L1007fs.
¶Comprising quinolones, cotrimoxazole and rifaximin. Data available from 421 patients (97.5%). Abbreviations: mutation (MUT); wild-type (WT); model for end-stage liver disease (MELD); Serum ascites albumin gradient (SAAG); White blood cell count (WBC); spontaneous bacterial peritonitis (SBP).